The main purpose of Phase II study is to determine the maximum tolerated and efficient dose of RBCs encapsulating L-asparaginase (NCT01523782) and Phase II/III study evaluating efficacy and safety in patient with ALL (NCT01518517). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.